This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Editor’s note: A livestream of the event will be embedded below at 1 p.m. Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does the system work for patients? And how can we fix it when it doesn’t? Read the rest…
LONDON — Medicare’s first-ever drugpricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.
WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive program will start to negotiate drugprices — let alone the substantive ones, Medicare chief Meena Seshamani said at a STAT event Tuesday.
I’m writing to you from San Diego, where STAT held an event during the American Academy of Neurology annual meeting this past weekend. We’ll get into a highlight from the event below, along with all the other biotech news today. Sign up to get our biotech newsletter in your inbox. Good morning.
Editor’s note: A livestream of the event will be embedded below at 1 p.m. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?
If you’ll also be there, come to our STAT event on Sunday night! I’ll be talking with researchers about the potential of using GLP-1 drugs for neurological conditions, and my Readout co-writer Meghana will be chatting with BMS’ head of development about the launch of their new schizophrenia drug Cobenfy.
“They talk in such generalities on this subject that it’s difficult for me to tell where they’re coming from,” he said at a STAT event Wednesday, speaking about top GOP senators’ approach to reforming the drugpricing middlemen who negotiate between pharmaceutical companies and insurers.
In any event, there is work to be done, so as always, we have assembled a few items of interest for you. Unlike then, Democrats have a starting place: The new bill represents an expansion of the major drugpricing legislation the party passed last year. But this is to be expected at this time of year, yes?
Between Covid-19, drugpricing legislation, and a dramatic turn of events in neuroscience, the last few years of biotech history have been volatile to the point of capriciousness. Predicting the future is famously a mug’s game.
DrugPricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the DrugPricing Transparency Congress on March 28-29, 2022! Visit www.informaconnect.com/drug-pricing-transparency for further details and to register.
Experts from across the industry will discuss how current and future drugpricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.
Say hi if you’re attending our STAT event on Friday night! Sign up to get our biotech newsletter in your inbox. Good morning. A big welcome to everyone coming to Chicago for ASCO this weekend. Read the rest…
Informa Connect’s DrugPricing Transparency Congress. Delivered as a Hybrid Event In-Person: November 9-10 | Philadelphia, PA Virtual: November 16-17 www.informaconnect.com/drug-pricing-transparency. Exclusive Offer for Drug Channels Readers: Use Promo Code 21DPT10 to Receive 10% off Your Registration.
They include a mechanized injector that gives robotic voice commands , a prefilled syringe pen, an ultra-high-dose nasal spray, and an autoinjector that the Pentagon has purchased for use in the event of a terrorist attack. Read the rest…
Well, this wraps up one of the most eventful weeks of the biotech year — ASCO, followed by BIO. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Anyone else as zonked as I am?
Today, we look at the biggest biotech events to watch this quarter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. And as my editor had to remind me (since I’m still in denial), we are indeed in the fourth quarter now.
Eliquis is one of 10 high-cost drugs the federal program has targeted first for negotiated prices. “The manufacturer of that drug spent most of 2020 in court trying to fend off generic competition,” she said at a Tuesday STAT event in Washington D.C. Continue to STAT+ to read the full story…
the curious story of the latest FDA drug approval, and a twist on the year’s biggest biotech event. Damian here with a look at pharma’s struggle to make inroads in D.C., Read the rest…
See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards. In the video below, I discuss how generic drugpricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute.
Damian here with a special thanks to everyone who joined us for STAT’s live event in New York City last night. Sign up to get our biotech newsletter in your inbox. Good morning, everyone.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. to 1:30 p.m. SPECIAL DISCOUNTS FOR GROUPS!
President Joe Biden has reiterated his pledge to take action against high drugprices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered at a White House event with US Senator Bernie Sanders, a long-time critic of the industry’s pricing policies in the US.
NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s drug lecanemab , according to remarks made by both a critic of other Alzheimer’s medicines and the CEO of the company that developed it.
In an unusual turn of events, an appeals panel ruled that the U.K.’s ’s cost effectiveness watchdog agency acted unfairly and exceeded its authority by failing to thoroughly explain why it declined to recommend a Johnson & Johnson medicine called Spravato for combating treatment-resistant depression.
However, winning in the Indian market requires a strategically thought-out India-specific strategy that accounts for the market nuances such as non-uniform payer coverage of specialty drugs, pricing schedules and varying levels of healthcare infrastructure.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. This event will be broadcast live on July 29, 2022 , from 12:00 p.m. This event is part of The Drug Channels 2022 Video Webinar Series.
The researchers did not see any severe adverse events linked to the drug, and there were no treatment-related discontinuations. The biotech plans to start a Phase 2b trial of the drug, called MET-097, in the fourth quarter of this year, with data expected in the first half of next year.
This page describes the event and explains how to purchase a registration to the live event. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. This event can be both a capstone of your annual learning and a touchpoint for the future. d/b/a Drug Channels Institute.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B DrugPricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m.
Upcoming Informa Connect Events: Speaker Programs Summit – February 27-March 1, 2023. DrugPricing & Transparency Congress – May 16-17, 2023. Medicaid & Government Pricing Congress – May 16-18, 2023. DrugPricing & Transparency Congress – May 23-24, 2023.
In a year of major change and outstanding questions, growing scrutiny on patent protection and drugpricing, and uncertainty around global price control measures and the Inflation Reduction Act, understanding the implications of new leadership and emerging mandates is critical. FDA Law Blog is a conference media partner.
We plan to catch up on sundry tasks, promenade with the official mascots and escort Mrs. Pharmalot to an event or two. This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda has possibilities. And what about you? This remains a fine time to enjoy the great outdoors.
ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Anyone who registered for the entire series will receive an email with a link to access the June event. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m.
Informa Connect-CBI’s 6th Edition DrugPricing Transparency Congress. November 16-17, 2020 | Virtual Event www.informaconnect.com/drug-pricing-transparency. Drug Channels Readers: View the complete agenda and register today. Be sure to use your exclusive promo DRUG30 to save $300 *.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m.
It’s time for our most popular event of the year! Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. Dr. Adam J. to 1:30 p.m.
ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Anyone who registered for the entire series should have received an email with a link to access the December event. Broadcast live on December 17, 2021. to 1:30 p.m.
As you work to navigate the evolving healthcare landscape, this annual event brings together 60+ expert speakers from 70+ companies to lead the critical discussions that will drive comprehensive market strategy, uniting Medicaid, Policy, Pricing, Contracting & Reporting thought leaders. All rights reserved.
Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, DrugPrice Transparency, Commercial Contracting or Chargebacks , we have you covered!
ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUGPRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines. View the panel discussion here.
Hybrid Event In-Person: November 17-19, 2021 in Philadelphia Virtual: November 22-23, 2021 www.informaconnect.com/gtn. Drug Channels readers will save 10% off when they use code 21DRCH10 and register prior to October 20th.*. Drug Channels readers will save 10% off when they use code 21DRCH10 and register prior to October 20th.*.
REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.
REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content